172 related articles for article (PubMed ID: 10233872)
1. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.
Maki K; Mitani K; Yamagata T; Kurokawa M; Kanda Y; Yazaki Y; Hirai H
Blood; 1999 May; 93(10):3216-24. PubMed ID: 10233872
[TBL] [Abstract][Full Text] [Related]
2. Subcellular localization of the MEN, MLL/MEN and truncated MLL proteins expressed in leukemic cells carrying the t(11;19)(q23;p13.1) translocation.
Kanda Y; Mitani K; Tanaka T; Tanaka K; Ogawa S; Yazaki Y; Hirai H
Int J Hematol; 1997 Aug; 66(2):189-95. PubMed ID: 9277049
[TBL] [Abstract][Full Text] [Related]
3. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
4. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
Thirman MJ; Levitan DA; Kobayashi H; Simon MC; Rowley JD
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12110-4. PubMed ID: 7991593
[TBL] [Abstract][Full Text] [Related]
5. The FEL (AF-4) protein donates transcriptional activation sequences to Hrx-Fel fusion proteins in leukemias containing T(4;11)(Q21;Q23) chromosomal translocations.
Morrissey JJ; Raney S; Cleary ML
Leuk Res; 1997 Oct; 21(10):911-7. PubMed ID: 9403001
[TBL] [Abstract][Full Text] [Related]
6. Translocation (8;12)(q13;p13) during disease progression in acute myelomonocytic leukemia with t(11;19)(q23;p13.1).
Yamamoto K; Nagata K; Tsurukubo Y; Inagaki K; Ono R; Taki T; Hayashi Y; Hamaguchi H
Cancer Genet Cytogenet; 2002 Aug; 137(1):64-7. PubMed ID: 12377416
[TBL] [Abstract][Full Text] [Related]
7. Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation.
Mitani K; Kanda Y; Ogawa S; Tanaka T; Inazawa J; Yazaki Y; Hirai H
Blood; 1995 Apr; 85(8):2017-24. PubMed ID: 7718874
[TBL] [Abstract][Full Text] [Related]
8. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.
Zeleznik-Le NJ; Harden AM; Rowley JD
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10610-4. PubMed ID: 7938000
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias.
Rubnitz JE; Behm FG; Curcio-Brint AM; Pinheiro RP; Carroll AJ; Raimondi SC; Shurtleff SA; Downing JR
Blood; 1996 Jun; 87(11):4804-8. PubMed ID: 8639852
[TBL] [Abstract][Full Text] [Related]
10. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.
Joh T; Yamamoto K; Kagami Y; Kakuda H; Sato T; Yamamoto T; Takahashi T; Ueda R; Kaibuchi K; Seto M
Oncogene; 1997 Oct; 15(14):1681-7. PubMed ID: 9349501
[TBL] [Abstract][Full Text] [Related]
11. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia.
Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD
Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Rat1 cells with dependence on the lysine-rich region.
Kanda Y; Mitani K; Kurokawa M; Yamagata T; Yazaki Y; Hirai H
J Biol Chem; 1998 Feb; 273(9):5248-52. PubMed ID: 9478981
[TBL] [Abstract][Full Text] [Related]
13. t(10;11)-acute leukemias with MLL-AF10 and MLL-ABI1 chimeric transcripts: specific expression patterns of ABI1 gene in leukemia and solid tumor cell lines.
Shibuya N; Taki T; Mugishima H; Chin M; Tsuchida M; Sako M; Kawa K; Ishii E; Miura I; Yanagisawa M; Hayashi Y
Genes Chromosomes Cancer; 2001 Sep; 32(1):1-10. PubMed ID: 11477655
[TBL] [Abstract][Full Text] [Related]
14. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).
Sobulo OM; Borrow J; Tomek R; Reshmi S; Harden A; Schlegelberger B; Housman D; Doggett NA; Rowley JD; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 1997 Aug; 94(16):8732-7. PubMed ID: 9238046
[TBL] [Abstract][Full Text] [Related]
15. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
16. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.
Shinobu N; Maeda T; Aso T; Ito T; Kondo T; Koike K; Hatakeyama M
J Biol Chem; 1999 Jun; 274(24):17003-10. PubMed ID: 10358050
[TBL] [Abstract][Full Text] [Related]
17. Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation.
Corral J; Forster A; Thompson S; Lampert F; Kaneko Y; Slater R; Kroes WG; van der Schoot CE; Ludwig WD; Karpas A
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8538-42. PubMed ID: 8378328
[TBL] [Abstract][Full Text] [Related]
18. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.
Pascual-Le Tallec L; Simone F; Viengchareun S; Meduri G; Thirman MJ; Lombès M
Mol Endocrinol; 2005 May; 19(5):1158-69. PubMed ID: 15650021
[TBL] [Abstract][Full Text] [Related]
19. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
[TBL] [Abstract][Full Text] [Related]
20. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.
Polak PE; Simone F; Kaberlein JJ; Luo RT; Thirman MJ
Mol Biol Cell; 2003 Apr; 14(4):1517-28. PubMed ID: 12686606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
